There may be an increased level of anxiety among research staff at Merck & Co. over the next few months as former Amgen executive Roger Perlmutter comes on board to replace Peter Kim as head of R&D. Perlmutter will have “broad discretion” to kill or move existing drug programs forward, according to Merck spokesperson Steven Cragle.
There may be an increased level of anxiety among research staff at Merck & Co. over the next few months as former Amgen executive Roger Perlmutter comes on board to replace Peter Kim as head of R&D. Perlmutter will have “broad discretion” to kill or move existing drug programs forward, according to Merck spokesperson Steven Cragle.
Dr Perlmutter who left Amgen in February 2012 after more than a decade overseeing the big biotech company’s research, was...
In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. After exploring the potential of amylin receptor agonists, we now look at myostatins, which analysts expect to generate peak sales of $30bn.
The drugmaker announced topline results from the Phase III ATTAIN-2 trial in overweight/obese patients with type 2 diabetes and plans to file for approval.
The China-headquartered company expects Phase II results from ASC30 later this year to outperform orforglipron and spark lots of big pharma interest.
OneSource Specialty CEO Neeraj Sharma discusses with Scrip exploratory talks with next-gen GLP-1 innovators, prospects for semaglutide generics and investment in Swedish firm Xbrane, among other topics.
The Danish firm’s board unanimously supports a $2bn take-private offer by PE firms Nordic Capital and Permira. A revised offer would seek to bypass the opposition of a major shareholder.
Head of hematology clinical development Andres Sirulnik talked to Scrip about the positive Phase III results for the siRNA medicine.
The Swiss giant is paying $30m upfront for rights to the Swedish firm’s BrainTransporter technology, its second brain-barrier breaching deal in as many months.
